VIROPRO (Pink Sheets: VPRO) today announced it has retained Cooper Global Communications LLC (“CGC”) to perform U.S. and international investor-relations functions to increase awareness of the Company in the global investment community.

"We are very pleased that CGC has joined the Viropro team as our investor relations consultant. CGC’s expertise in branding, media, and investor outreach will help us to identify investors, analysts, and strategic parties that recognize the value of our technology transfer expertise. Given the international scope of our business and anticipated near-term milestones, we look forward to educating the investment community about our business, achievements to date, and future progress,” stated Rajiv Datar, President and CEO of Viropro.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

About Cooper Global Communications, LLC

Founded by Richard Cooper, a seasoned and highly-respected Wall Street veteran, Cooper Global Communications is a boutique investor relations firm with a highly-seasoned team of investment/financial professionals who are committed to offering high-quality service to their clients. Since its origins in 1989, Cooper Global Communications has achieved unparalleled success.

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

Viropro (CE) (USOTC:VPRO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Viropro (CE).
Viropro (CE) (USOTC:VPRO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Viropro (CE).